High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 PURPOSE: To characterize the pharmacokinetics of topotecan in a population model that ...
Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor ...
Although body weight affected pharmacokinetics, the investigators said dosing adjustments based on weight were not warranted. A new report shows the pharmacokinetic properties of Dupixent (dupilumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback